GenSight will participate to the American Academy of Ophthalmology in Chicago and will give an oral presentation on its lead product candidate, GS010, to treat Leber’s Hereditary Optic Neuropathy (LHON).

GS010 – Leber’s Hereditary Optic Neuropathy (LHON) 

Oral presentation:  Efficacy of rAAV2/2-ND4, an Investigational Gene Therapy for ND4 LHON: Top-line Results of Phase 3 Clinical Trial REVERSE

  • Presenting Author:  Mark L. Moster, MD, Neuro-Ophthalmology, Wills Eye Hospital and Professor of Neurology and Ophthalmology at Thomas Jefferson University, Philadelphia, PA (Investigator in REVERSE and RESCUE trials)
  • Session Date/Time: Monday, October 29, 2018, 2:12 PM – 2:19 PM
  • Topic Title: Retina, Vitreous
  • Room: S405
  • Final abstract number: PA066